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Abstract: The parvulin-type peptidyl-prolyl cis/trans isomerase Pin1 is subject of intense biochemical and clinical research 
as it seems to be involved in the pathogenesis of certain cancers and protein folding illnesses like Alzheimer’s and Parkin-
son’s disease. In addition to Pin1, the human genome only contains a single other parvulin locus encoding two protein 
species—Par14 and Par17. Much less is known about these enzymes although their sequences are highly conserved in all 
metazoans. Parvulin has been proposed to function as Pin1 complementing enzyme in cell cycle regulation and in chroma-
tin remodelling. Pharmaceutical modulation of Par14 might therefore have beneﬁ  ts for certain types of cancer. Moreover, 
the Par17 protein that has been shown to be conﬁ  ned to anthropoid primate species only might provide a deeper understand-
ing for human-speciﬁ  c brain development. This review aims at stimulating further research on Par14 and Par17 that are 
overlooked drug targets in the shadow of an overwhelming plethora of Pin1 literature by summarising all current knowledge 
on these parvulin proteins.
Introduction
Protein mediated biological processes are strictly regulated in a spatial and temporal manner. This 
regulation is strongly affected by peptidyl prolyl cis/trans isomerases (PPIases) both at the stage of 
protein folding as well as within the native state.
1 There are PPIases that bind to immunosuppressant 
drugs and hence are referred to as immunophilins.
2,3 These are the cyclophilins which bind to 
cyclosporin A and the FKBPs (FK506 binding proteins) which are inhibited by FK506 and rapamy-
cin. Parvulins are a third class of PPIases conserved from bacteria to man. A prominent parvulin is 
the mitotic regulator Pin1
4 involved in cell cycle regulation and protein folding disorders such as 
Alzheimer’s or Parkinson’s disease. The vast amount of literature about this phosphorylation 
speciﬁ  c PPIase has been reviewed numerous times, here only giving some of the most recent 
references.
5–12
The human genome contains one more parvulin gene besides Pin1—a locus on Chromosome Xq13 
encoding two protein species, Par14 and Par17.
13 The core sequence of these parvulins is highly con-
served in all multi-cellular organisms examined so far, but absent from yeasts. Within the human 
genome two intron-less parvulin pseudogenes on chromosome 1 and 15 can be found;
13 but since they 
are truncated at the 5′ end and they contain several point mutations, they are not expressed. The occur-
rence of Par17 has furthermore been shown to be conﬁ  ned to the species of great apes and humans 
only
14 and thus might provide a deeper understanding of human-speciﬁ  c brain development. Parvulin 
proteins might therefore turn out to be valuable drug targets besides the well known mitotic regulator 
protein Pin1.
Identiﬁ  cation of Parvulin Proteins
The ﬁ  rst member of the parvulin family of PPIases was the E. coli enzyme Par10.
15,16 It is a cytosolic 
protein solely consisting of the PPIase domain with no additional N- or C-terminal extensions. Its name 
was derived from the Latin word parvulus (meaning tiny) due to its low molecular weight of about 
10 kDa as compared to the larger FKBPs and cyclophilins. The substrate speciﬁ  city of Par10 resembles 
that of FKBP isomerases with a preference for bulky, hydrophobic side chains preceding the proline 
residue;
17 the cellular function of this protein is still elusive.12
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Human Pin1 was then identiﬁ  ed by two-hybrid 
screening as a protein interacting with NIMA 
kinase;
4 in addition, Pin1 suppresses the growth 
inhibiting effect of this kinase. Using tetrad analysis 
as well as plasmid shufﬂ  ing experiments the same 
study showed that human Pin1 can substitute for 
yeast Ess1 (see below) both in haploid and diploid 
cells.
4 Depletion of Pin1 from yeast or HeLa cells 
induced mitotic arrest
4 and Pin1 inhibition caused 
apoptosis in a ras-transformed tumour cell line
18 
whereas HeLa cells over-expressing Pin1 arrest in 
G2 phase of the cell cycle. Pin1
−/− mice are viable 
but show cell cycle defects resembling cyclin D1 
knockout
19,20 and defects in spermatogenesis.
21,22 
Pin1 has a strong preference for phosphorylated 
serine or threonine side chains preceding proline.
23
The only yeast parvulin, Ess1, was cloned way 
before the identiﬁ  cation of Pin1 as a protein essen-
tial for growth,
24 however its enzymatic activity 
as a PPIase was only described later.
25,26 One of 
its major cellular substrates seems to be the multi-
phosphorylated C-terminal domain of RNA 
polymerase II
27,28 as this isomerase shares the 
preference for phosphorylated Ser/Thr-Pro motifs. 
Intriguingly, the essential function of Ess1 is 
already fulﬁ  lled at 0.5 per cent of wild type protein 
levels.
29 The homologous protein in Candida albi-
cans is essential for growth and morphogenetic 
switching,
30 while the corresponding one in Cryp-
tococcus neoformans is not required for normal 
growth and only needed for virulence.
31 Pin1/Ess1 
related parvulin sequences are now available from 
a variety of different eukaryotic organisms.
32
Human parvulins different from Pin1
Another human parvulin was cloned as a homo-
logue of human Pin1 and E. coli parvulin Par10. 
It consists of a 1.0 kilo-base cDNA encoding a 156 
amino acids protein named Par14
33 or Eukaryotic 
Homolog of Parvulins (EHPV)
34 and is assumed 
to be involved in cell cycle progression or chro-
matin remodelling.
35,36 For unknown reasons, the 
name “Pin4” was assigned to this protein in public 
databases meaning “protein interacting with NIMA 
kinase 4”; however, such interaction has never been 
shown for Par14. The protein contains a C-terminal 
PPIase domain that has 34% and 39% sequence 
identity with the PPIase domains of E. coli Par10 
and human Pin1, respectively. In addition, Par14 
has an N-terminal ﬂ  exible domain rich in lysine, 
serine and glycine residues.
37,38
Northern blot analysis of human Par14 expression 
using the very same multiple tissue membranes 
in two studies
33,34 showed an enhanced expression 
in heart and skeletal muscles but weak signals in 
brain and lung tissues. Par14 expression in pla-
centa, liver, kidney and pancreas was at moderate 
levels. In addition, an mRNA dot-blot showed 
Par14 expression in a variety of tissues, but notably 
at relatively lower levels in neuronal tissues.
34
Parvulin 14 was proposed to partially com-
pensate for Pin1 loss in mammalian cells as its 
mRNA and protein levels were up-regulated in 
Pin1
−/− mouse endothelial ﬁ  broblasts (MEFs).
39 
The very same study purported that siRNA 
depletion of Par14 inhibited growth of Pin1
−/− 
MEFs much stronger than Pin1
−/− MEFs re-
expressing Pin1.
39 Furthermore, Par14 has been 
proposed as a Pin1 complementing enzyme in 
cell cycle regulation
39 and chromatin remodel-
ling.
35 However, compensation for Pin1 loss is 
not complete as Par14 failed to rescue the 
deletion of the yeast parvulin Ess1.
40 Moreover, 
its comparably low activity was not speciﬁ  c for 
phosphorylated peptide motifs.
33 This suggests 
divergent, but partially overlapping cellular 
functions for the two human parvulins. Comple-
mentation or cross talk between different PPIases 
has already been studied in yeast. There, the 
cyclophilin CypA is able to interact with and 
complement for the yeast parvulin Ess1.
27,41,42
Besides Par14, a second protein species is 
encoded by the parvulin gene on chromosome 
Xq13 with an elongated N-terminus.
13 The 
extended mRNA of Par17 is only transcribed in 
low copy numbers compared to Par14 with about 
0.5% of total parvulin mRNA in skeletal muscle 
and liver tissues and up to 1.5% in brain and epi-
thelial tissues.
13 The Par17 protein is targeted to 
the mitochondrial matrix with the N-terminal 
domain acting as mitochondrial targeting peptide.
14 
As this mitochondrial targeting signal is only 
encoded within the genomes of great apes and 
humans, this might be the most recently evolved 
cellular targeting peptide known to date.
14 The 
domain structure of different parvulin proteins is 
shown in Figure 1.
The emergence of two parvulin genes 
within Eukarya
Pin1 and Par14 sequences are found in all multi-
cellular organisms from N. crassa and C. elegans 13
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to man, whereas yeasts contain only one parvulin 
homolog called Ess1. Compared with the 
cyclophilin and FKBP repertoires, the parvulin 
repertoires of eukaryotic organisms are relatively 
small with just two parvulins in most metazoans.
32 
One might therefore ask when this second parvulin 
was acquired. A detailed analysis of the PPIase 
repertoires of a variety of fungal genomes conﬁ  rms 
the existence of a single parvulin gene within the 
phylogenetic clade Saccharomycotina that includes 
for example Saccharomyces cerevisiae or Candida 
albicans; only in the clade of Pezizomycotina 
including for instance Aspergillus nidulans or 
Neurospora crassa two parvulin genes are found.
43 
Since then, parvulin coding sequences have been 
highly conserved as seen on the alignment in 
Figure 2 with the Par14 sequences from human 
and A. nidulans sharing 55% and the Pin1 
sequences 57% identity on the amino acid level. 
In contrast, the parvulin-type PPIases only share 
24% and 32% identity within A. nidulans or 
humans, respectively. Hence, studying parvulin 
proteins in ﬁ  lamentous fungi could yield valuable 
insights into their cellular functions.
Comparison of Structure 
and Mechanism of Parvulin Proteins
The primary structure of the Par14 and Pin1 PPIase 
domains show striking differences between the two 
when aligned with the ClustalW program (not 
shown). The large phospho-binding loop of Pin1 
is missing in Par14; this protein instead has an 
insertion of ﬁ  ve amino acids near the C-terminal 
end of the PPIase domain. Notably, a coupled 
exchange of residues can be observed within the 
N-terminal β-sheet: Cys57 and Val62 in all Pin1 
sequences are replaced by Val40 and Cys45 in all 
Figure 1. Schematic overview on different parvulin proteins. Bacterial, plant and human parvulin representatives are depicted with their 
domain structure. E. coli SurA contains two PPIase domains (blue and gray) and large N- and C-terminal extensions. E. coli Par10 does not 
contain any extensions or additional loops—as one of the scarce parvulin sequences from Archaea, PinA from Cenarchaeum symbiosum 
(SwissProt: O74049). There are phospho-speciﬁ  c parvulins (indicated with the ribbon-like loop) both with and without WW domain. The WW 
domain is connected to the catalytic domain by a ﬂ  exible linker in human Pin1.
66 Par14-like parvulins contain an N-terminal basic domain 
(+ + +) and a ﬁ  ve amino acid insertion (loop) between the C-terminal helix and beta-strand of the PPIase domain. An alpha-helical extension 
(barrel) to this sequence is hominid-speciﬁ  c.14
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Par14-type proteins. More elusive than the 
ClustalW alignment was a structure-based com-
parison of the PPIase domains including phyloge-
netic information (Fig. 2). From this figure it 
becomes clear that conserved residues between 
Par14 and Pin1 mainly locate to secondary struc-
ture elements. In addition, the Par14 speciﬁ  c inser-
tion of ﬁ  ve amino acids C-terminal to the last helix 
is contained in all Par14 sequences but without 
obvious conservation of sequence.
The NMR solution structure of Par14 was 
solved independently by two groups (PDB acces-
sion numbers 1EQ3
37 and 1FJD
38). The global fold 
of the PPIase domain consists of a twisted four-
stranded β-sheet wrapping around the C-terminal 
helix; the other helices stacking on the other side 
of the central β-sheet. Structural similarities to 
FKBP12 and Pin1 were identiﬁ  ed in Par14 as its 
secondary structure elements show the same topo-
logical arrangement as in Pin1 crystal structure 
1PIN.
37,44 An overlay of Pin1 and Par14 1EQ3 
structures as well as a comparison between the two 
Par14 structures is depicted in Figure 2A and B.
When compared to the structure of the epony-
mous parvulin Par10 from E. coli (1JNT
45), Par14 
shares nearly all secondary features with this bac-
terial parvulin. Worth mentioning, Par10 contains 
a Gly76-Pro77 dipeptide in cis conformation
45 
structurally corresponding to Asp113-Pro114-
Pro115 in the Par14 structures where such strong 
constrains towards the cis conformation has not 
been observed. Hitherto, more parvulin structures 
are available from Bacillus subtilis PrsA (1ZK6
46), 
Arabidopsis thaliana Pin1 (1J6Y
47), E. coli SurA 
(1M5Y
48) and Candida albicans Ess1 (1YW5
49). 
Although the parvulin structures from bacteria and 
fungi may be used for the development of anti-
bacterial and anti-fungal drugs, none of the struc-
tures mentioned has an insertion corresponding to 
Par14 Val103 to Asp107. Hence, this insertion 
Figure 2. Alignment of parvulin and Pin1 sequences from different multicellular organisms. Pin1 and Par14 structures 1PIN and 
1EQ3, respectively, were aligned by DALILite.
67 Following sequences were obtained from SwissProt and added to this alignment: Par14_
Human, Q9Y237; Par14_Mouse, Q9CWW6; Pin2_Caele, Q9NAF9 (Y48C3A.16); Par14_Drome, Q9VBU4 (CG11858); Par14_Neucr, Q7RYY4; 
Pin4_Emeni, Q5B5W1 (Aspergillus nidulans or Emericella nidulans); Pin1_Emeni, Q5AZY5; Ssp1_Neucr, Q7RVY7; Dodo_Drome, P54353; 
Pin1_Mouse, Q9QUR7; Pin1_Human, Q13526. The start of the PPIase domain within these sequences is given. All but Pin1_Emeni end at 
the position indicated by an asterisk (*). The Pin1_Emeni sequence contains 26 additional residues. 1EQ3, 1PIN1: PDB entries where the 
secondary structure information was taken from. Residues believed to be important for PPIase activity are highlighted in black when con-
served between Par14 and Pin1, otherwise in gray.15
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seems to be conﬁ  ned to parvulins from multicellular 
eukaryotes only.
The Par14 speciﬁ  c loop region 
as a putative protein docking site
Par14-type PPIase sequences from metazoans 
contain a speciﬁ  c extension between the third 
β-strand and the C-terminal α-helix, but a 
functional role for this part of the protein has not 
been discussed so far. This region is at least 10 Å 
away from the putative active site of the protein.
37 
Hence, a role in speciﬁ  c interaction with other 
biopolymers is more likely rather than a direct 
involvement in substrate binding. The Val103-
Asp107 insertion constitutes a flexible loop 
Figure 3. Structural comparison between different parvulin structures. Overlay of the Par14 structure 1EQ3 in blue with A) Pin1 (1PIN) 
in orange; B) the Par14 structure 1FJD in gray and C) Par10 (1JNT) in cyan. The Par14 speciﬁ  c insertion is marked with an asterisk (*) in 
both views in A. All structural alignments were done with DALILite.
67 Left column, front view; right column, back view.16
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surrounded by hydrophobic side chains of Met55, 
Leu58, Met106, Pro109, Val110, Phe111, Pro114 
and Met126
37 suggesting this part of Par14 to be 
a potential docking site for other proteins.
The two Par14 solution structures differed in 
the very same region between amino acids Pro102 
and Pro114 (see comparison of 1EQ3 and 1FJD in 
Figure 2B). As mentioned above, the structure of 
the E. coli homologue
45 contains a Gly-Pro 
dipeptide exclusively in cis conformation at the 
position corresponding to Asp113-Pro114-Pro-115 
(Fig. 2C). Therefore, the observed structural 
heterogeneity seen at this site of Par14 might rep-
resent native-state proline isomerisation. Whether 
a crystallographic analysis of Par14 reveals an 
exact and non-ambiguous geometry of this loop 
region remains to be determined in the future.
Dividing parvulin proteins 
into subfamilies
From an enzymatic point of view, one can divide 
parvulin PPIases into at least two subfamilies.
17 
Clearly, one group prefers phosphorylated sub-
strates as has been demonstrated for human Pin1, 
yeast Ess1 and some plant parvulins. Concomitant 
to the preference of phosphorylated substrates, the 
Pin1-like parvulins comprise the above mentioned 
loop between the N-terminal β-strand and α-helix 
of the PPIase domain (see Fig. 1) that is involved 
in phospho-peptide recognition. All these enzymes 
display exceptionally high catalytic activities (kcat/
KM) towards Ser/Thr-Pro substrates modiﬁ  ed by 
phosphorylation.
17 The presence or absence of a 
WW domain N-terminal to the PPIase is not suf-
ﬁ  cient to assign a parvulin to this class of enzymes 
as deletion of Pin1’s WW domain has no effect on 
the in vitro activity of the enzyme.
50 A more mean-
ingful criterion for assigning parvulins to the Pin1-
like sub-group is the ability to complement the 
otherwise lethal Ess1 loss in S. cerevisiae.
40,51
To group the remaining parvulins is a rather 
difﬁ  cult attempt. They have been described as a 
group of proteins with varying substrate speciﬁ  city 
and with poorly characterised cellular function
46 
with human Par14 and the bacterial parvulins 
belonging to this subfamily. The observed 
kcat/KM values varied within a range from 10
3 to 
107 M
−1 s
−1 for several such parvulins.
17 To pool 
all these parvulins together in one other subfamily 
just on the basis of lack of knowledge neglects 
the very different catalytic activities of certain 
parvulins. Human Par14 and E. coli Par10, for 
instance, are two enzymes sharing a rather unspe-
ciﬁ  c substrate recognition pattern.
40 Apparently, 
these two enzymes differ a lot from each other: 
E. coli Par10 displayed with 1.35 × 10
7 M
−1 s
−1 
towards the peptidic substrate Suc-ALPF-pNA an 
enzymatic activity comparable to human Pin1 
whereas Par14’s reported activity of 3.9 × 10
3 
M
−1 s
−1 towards Suc-ARPF-pNA was at a lower 
limit of detection.
33 Nevertheless, E. coli Par10 
does catalyse the proline-limited folding of a vari-
ant of ribonuclease T1 at least 100-fold slower 
than the isomerization of the above mentioned 
peptide.
52 The real substrate for Par14 might have 
escaped identiﬁ  cation so far.
Catalytic residues in parvulin proteins
Residues essential for catalysis have been proposed 
for Pin1-like parvulins based on a complex struc-
ture of Pin1 with an Ala-Pro dipeptide and a sul-
phate bound to the active site
44 in line with 
site-directed mutagenesis experiments.
26,44 H59, 
C113, S154 and H157 have been observed close 
to the peptide bond of the ligand. Some of the 
residues of the putative substrate binding pocket 
are not contained in the other group of parvulins 
as seen in Figure 1 with Pin1 S154 being exchanged 
by F120 in the Par14 sequence.
The most notable difference is Cys113 of Pin1 
being replaced by Asp74 in Par14.
33 This Cys113’s 
involvement in the catalysis of Pin1 was postulated 
to act as a nucleophile. Pin1 Cys133Ala and E. coli 
Par10 Cys41Ala mutants displayed more than 100-
fold reduced catalytic activities compared to the 
wild-type.
44 Because difﬁ  culties have been reported 
in detecting very low isomerase activities,
34 one 
could ask whether parvulins with an aspartic acid 
at the corresponding position are active PPIases at 
all. Their isomerase activity towards peptidic sub-
strates is rather small, but deﬁ  nitively has been 
observed with Par14,
33 SurA
53 and PrsA.
54 In addi-
tion, mutating the Asp residue in PrsA to Ala 
(D154A) resulted in a protein with 50% remaining 
activity towards the peptide Suc-AKPF-pNA rela-
tive to wild-type PrsA.
46,54
The role of several residues has recently been 
challenged formerly believed to be crucial for Pin1 
function. In a mutagenesis screen, Behrsin and col-
leagues isolated a variety of Pin1 mutants which 
were still able to functionally replace yeast Ess1.
55 
Replacement of C113 by serine markedly reduced 17
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Pin1 function
55 as shown before.
44 Exchanging this 
very cysteine with an aspartic acid however resulted 
in no detectable loss in Pin1 function both in yeasts 
and in the puriﬁ  ed recombinant protein.
55 In spite 
of the surprising properties of the C113D mutant, a 
C113N mutation resulted in an inactive enzyme. As 
a result, cysteine and aspartic acid at this position 
are both compatible with PPIase activity and the 
role for C113 as a nucleophile within the catalytic 
process
17 is worth to be reconsidered. More struc-
tures of FKBP and parvulin proteins in complex 
with putative substrates might yield further insights 
into the catalytic mechanism of these enzymes.
What is the Function of Par14?
Despite eight years since its discovery, the function 
of Par14 still remains obscure. There are no known 
naturally occurring mutations associated with the 
human parvulin locus on chromosome Xq13. We 
are not aware of any knockout study of this protein 
in mice. Moreover, RNAi against the respective 
Par14 homologue have not caused an observable 
phenotype in two large-scale C. elegans RNAi 
screens. One searched for embryonic lethality, 
abnormal morphology or maternal sterility,
56 the 
other for the phenotypes abnormal postembryonic 
development or lethality.
56,57 Taken the very same 
degree of conservation between Par14 and Pin1 
proteins within multi-cellular organisms and the 
partial compensation for Pin1 loss, Par14 is rather 
unlikely a spare coding sequence but its function 
is yet to be revealed in the future.
In evolutionary terms it could have been neces-
sary to have highly active unspeciﬁ  c parvulins in 
primordial cells. Nowadays, the prokaryotic parvu-
lins might resemble these common ancestors most 
closely. More speciﬁ  c parvulin PPIases could have 
emerged within the evolution of Eukarya. Pin1-type 
parvulins fulﬁ  l the need to isomerise special Xaa-Pro 
bonds i.e. those bonds that are additionally retarded 
in their rotation by phosphorylation. A similar evo-
lutionary need might have provoked the emergence 
of Par14-type parvulins. Neither Pin1- nor Par14-
like parvulins have experienced an expansion during 
metazoan evolution as both fungi and mammals 
only contain one representative each. There is how-
ever an additional parvulin gene predicted in the 
genome of the green alga Chlamydomonas rein-
hardtii. The encoded protein contains a phospho-
binding loop and an N-terminal forkhead domain 
instead of a WW moiety.
58 Another survey on PPIase 
genes described a parvulin related protein of 44 kDa 
with a central parvulin domain in the fruit fly 
Drosophila melanogaster.
32
Par14 is localised to nucleus 
and cytosol and Par17 to mitochondria
There are only few hints for the function for Par14- 
type parvulins. The Par14 protein was initially 
detected within crude nuclear, cytosolic and mito-
chondrial fraction of human HEK 293 cells.
34 
Immuno-gold labelling revealed the protein to 
localise throughout the cell with certain enrichment 
in the nuclear matrix.
34,59 At that time it was how-
ever unclear how this protein could reach the 
mitochondrial matrix. Independent follow up stud-
ies described Par14 within the cytosol and slightly 
enriched in the nucleus.
35,36,60 Shuttling between 
these two cellular compartments is regulated by 
phosphorylation on Ser19 within the N-terminal 
ﬂ  exible domain most likely by casein kinase 2.
35 
Although this part of Par14 is rich in basic residues, 
a classical nuclear localisation signal (NLS) could 
not be identified; N-terminal deletion studies 
though allowed narrowing the sequence down to 
Ser7 to Lys14 that functioned as NLS.
36
A second parvulin protein species recently 
described might explain the amount of Par14 
observed in mitochondria. By alternative transcrip-
tion initiation an elongated messenger RNA is made 
at the parvulin locus on the X chromosome.
13 This 
longer mRNA encodes an extended parvulin protein 
with additional N-terminal 25 residues, designated 
Par17 whose expression in human cells could be 
confirmed.
13 The sequence between Met3 and 
Ala23 of Par17 forms an amphipatic α-helix that 
targets the protein to mitochondria where it is 
imported to the matrix in a membrane potential and 
time dependent manner.
14 This protein might have 
resulted in the signals described above. Assuming 
that Par17 fulﬁ  ls a similar function within the mito-
chondria as Par14 in the nucleus, this function 
would be limited to mitochondria of great ape spe-
cies and man as only the genomes of these species 
do contain the Par17 coding sequence.
14
Par14 and Par17 as DNA-binding 
proteins
Within the nucleus, Par14 was reported to bind to 
double-stranded DNA.
36 Based on certain similar-
ity to the HMGB motifs in sequence-specific 18
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transcription factors like SRY and Lef-1 bent DNA 
oligonucleotides were tested for binding with 
Par14 resulting in AT-rich DNA octamers binding 
in the sub micro-molar range to Par14; the basic 
N-terminal part with sequence similarity to the 
chromatin-unfolding domain of HMGN proteins 
was indispensable for high afﬁ  nity DNA binding.
36 
Such bent AT-rich segments of DNA are supposed 
to dictate nucleosome positioning 
61 and play a role 
in transcription initiation suggesting involvement 
of Par14 in these processes. Par17 was equally well 
able to bind DNA at physiologic salt concentra-
tions.
14 Hence, it is reasonable to assume a function 
for Par17 associated with the mitochondrial 
nucleoid.
Besides DNA binding, Par14 was reported to 
bind to pre-ribosomal ribonucleo-protein parti-
cles.
60 In GST pull down experiments followed by 
MS identiﬁ  cation of associated biopolymers Par14 
was reported to be part of the preribosomal ribo-
nucleoprotein (pre-rRNP) complexes and as inter-
acting with ﬁ  bronectin, p160 (Myb-binding), p58 
cyclindependant kinase (a G2/M-speciﬁ  c protein 
kinase) and α- and β-tubulin.
60,62 Puzzling in this 
report was the ﬁ  nding that the basic domain alone 
was sufﬁ  cient for most of these interactions. There-
fore, the mode of interaction between Par14 and 
the just mentioned proteins might include relatively 
global ionic interactions. Taken together, the scarce 
available information on Par14 interactions in a 
cellular context suggest a function for this highly 
conserved protein in chromatin structure regula-
tion, transcription and/or ribosome biogenesis.
How to Target Par14-Type Parvulins?
Despite of a variety of studies regarding inhibitors 
of Pin1 that have been reviewed recently,
63 there 
is only one study claiming the development of 
Par14 inhibitors.
39 Within this study, a small 
directed compound library was screened for Pin1 
inhibitors that was enriched in low-molecular-
weight chemicals containing double-ring structures 
resembling the known, but unspeciﬁ  c parvulin 
inhibitor juglone.
64,65 Candidate compounds were 
further derivatised yielding two Pin1 inhibitors 
with about 1.5 µM afﬁ  nity that inhibited several 
Pin1 expressing cancer cell lines.
39 The only argu-
ment for denoting theses two molecules also as 
Par14 inhibitors was molecular modelling using 
InsightII (Accelrys Inc) and Sybyl (Tripos Inc) 
softwares. These modelling studies indicated a 
supposedly ﬁ  tting arrangement of side chains in 
Par14 also allowing binding of the reported Pin1 
inhibitors. Both a direct interaction of these com-
pounds with recombinant Par14 and the inhibition 
of its already weak PPIase activity still need to be 
demonstrated experimentally.
The attempt to develop competitive PPIase 
inhibitors against Par14 analogous to existing Pin1 
modulators seems not very promising to us due to 
the hardly detectable PPIase activity described 
above and evidence that Par14 functions rather as 
a binding module than as a PPIase enzyme. In 
contrast, we here suggest the development of low-
molecular-weight substances destabilising parvu-
lin possibly by irreversibly reacting with the 
conserved cysteine 45 residue. Targeting the Par14 
speciﬁ  c loop between Val103 and Asp107 that 
constitutes a putative protein-protein interaction 
surface together with the surrounding side chains 
might be another way of interfering with parvulin 
function. This could be achieved by speciﬁ  c small 
proteinous binders. Disturbing the cellular locali-
sation of Par14 and Par17 proteins could be a third 
possibility to inﬂ  uence the function of these pro-
teins.
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